Wednesday 19th March - Main Conference Day OneWednesday, 19 March 2025 - PT (Pacific Time, GMT-08:00)

• Spotlight on the complexities of CGT manufacturing;
• How do we address these complexities by standardizing the path to commercialization;
• What innovation and platforms exist to make CGTs more accessible now and in the future?

• How do manufacturers achieve scalability without compromising product quality?
• Increasing batch sizes and maintaining consistency to reduce costs;
• How early is too early to consider strategy for scaling up?
• Strategies to ensure reproducibility, robustness and cell product quality to uphold therapeutic efficacy;
• Harnessing rapid/integrated platforms and process improvements to broaden cell therapy impact;
• Accelerating delivery to patients and catering to increased demand at a clinical and commercial scale.

Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.

Contact us today to learn more: Partners@informaconnectls.com

Over the past 3 years the joining of cell and gene therapy material quality with the joint auditing model has proven to not only increase safety but also decrease money spent. The joint audit model can partner confidentially C&G organizations together to audit material suppliers, which in turn provides a much more robust audit, and return. This presentation will dive into the joint auditing model and provide case examples on best practices as well as guidance.

• Pointers for evaluating academic/early stage programs before technology transfer to a commercial CDMO;
• Choosing and interacting with an optimal CDMO for streamlining manufacturing protocol development;
• Practical tips to avoid time and cost in early manufacturing planning.

• Ensuring the commercial sustainability of cell & gene therapies;
• Tackling barriers and identifying opportunities for commercialization;
• Innovative payment models in the US and globally;
• Strategies for attracting investment to ensure smooth transition from bench to bedside.